Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune, Cardiovascular, and Neurodegenerative Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VIP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VIP Recombinant Protein (Active Peptide/Fc-Fusion) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for receptor binding assays. |
View VIP Products |
| Gene Delivery | VIP Promise-ORF / Lentivirus Full-length ORF for overexpression studies and cell-based functional assays. |
View VIP Products |
| Benchmark Ab | Anti-VIP Recombinant Antibody Recombinant positive control for neutralization and ELISA-based detection. |
View VIP Products |
| Validator | VIP siRNA Set For target knockdown verification and functional specificity validation. |
View VIP Products |
| Related Target A | VPAC1 (Vasoactive Intestinal Peptide Receptor 1) Primary GPCR mediator of VIP signaling. Crucial for selectivity and safety screening. |
View VPAC1 Products |
| Related Target B | VPAC2 (Vasoactive Intestinal Peptide Receptor 2) Homologous GPCR mediator. Essential for differential agonist/antagonist profiling. |
View VPAC2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation & Signaling | Lentivirus for VPAC1/VPAC2 stable cell line construction to preserve native GPCR conformations. |
| Target Specificity & Receptor Profiling | High-purity human, mouse, and cyno ortholog proteins verified by mass spectrometry to eliminate cross-reactivity. |
| Lack of Controls | Recombinant Clinical Benchmark Antibodies included for assay validation and comparative screening. |
| False Positives | Sequence-verified siRNA sets included for target knockdown validation. |
Live VIP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic potential of Vasoactive Intestinal Peptide (VIP) and its receptors (VPAC1 and VPAC2) spans across pulmonary arterial hypertension (PAH), chronic inflammatory diseases (COPD, Sarcoidosis), and neurodegenerative disorders. Because native VIP is rapidly degraded in vivo (half-life < 2 minutes), current drug discovery is shifting away from wild-type peptide administration toward half-life-extended VIP analogs (such as PEGylated forms or Fc-fusions), VPAC-selective small molecules, and targeted monoclonal antibodies.
As next-generation peptide-drug conjugates (PDCs) and selective GPCR modulators enter preclinical and clinical phases, the demand for highly precise screening platforms is escalating. Developing molecules that can selectively target VPAC1 or VPAC2 without off-target systemic vasodilation remains the primary hurdle for the next wave of VIP-targeted therapeutics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Long-acting Peptide Agonists | PhaseBio, Vance Pharm | Pulmonary Arterial Hypertension (PAH), ARDS | VPAC1/VPAC2 activation assay (Need stable cell lines via Lentivirus) |
| Monoclonal Antibodies | Academic / Biotech Consortia | Oncology, Neuroinflammation | Epitope mapping & binding affinity (Need high-purity VIP-Fc proteins) |
| Peptide-Drug Conjugates (PDCs) | Oncology-focused Biotechs | Solid Tumors (VPAC1 overexpressing) | Internalization and receptor-mediated cytotoxicity assays |